Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Argatroban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 7/20 | 0.82 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.77 |
| ▸ | F10 | P00742 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | PLAT | P00750 | 1/20 | 0.77 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.77 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Argatroban SCHEMBL23356536 | 1.00 | F2 (0.82) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL7279618 | 1.00 | F2 (0.82) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL29501077 | 1.00 | F2 (0.82) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL1470919 | 1.00 | F2 (0.82) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL3447908 | 1.00 | F2 (0.82) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL4374 | 0.99 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL1817517 | 0.99 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL4933701 | 0.99 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL3175687 | 0.99 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL1145308 | 0.99 | F2 (0.83) | F2PRSS1F10LMNAPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114689768-A | Separation detection method for impurity content in argatroban monohydrate | 汉寿康运医药科技有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-110981934-B | Synthetic method of argatroban hydrate | 鲁南制药集团股份有限公司 | 2021-05-25 | — | — | CN | claimed |
| WO-2021093374-A1 | METHOD FOR SYNTHESIZING ARGATROBAN HYDRATE | 山东新时代药业有限公司 | 2021-05-20 | — | — | WO | claimed |
| CN-111961114-A | Argatroban intermediate and preparation method and application thereof | 扬州中宝药业股份有限公司 | 2020-11-20 | — | — | CN | claimed |
| CN-111760129-A | Ready-to-use prefilled argatroban injection product and preparation method thereof | 太阳升(亳州)生物医药科技有限公司 | 2020-10-13 | — | — | CN | claimed |
| CN-110981934-A | Synthetic method of argatroban hydrate | 鲁南制药集团股份有限公司 | 2020-04-10 | — | — | CN | claimed |
| CN-105367622-B | A kind of argatroban compound | 四川科瑞德制药股份有限公司 | 2019-12-03 | — | — | CN | claimed |
| CN-103923168-B | A kind of preparation method of argatroban monohydrate | 山东新时代药业有限公司 | 2018-08-24 | — | — | CN | claimed |
| CN-105367622-A | Argatroban compound | SICHUAN CREDIT PHARMACEUTICAL CO LTD | 2016-03-02 | — | — | CN | claimed |
| EP-2285799-B1 | METHOD FOR PREPARING ARGATROBAN MONOHYDRATE | LUNDBECK PHARMACEUTICALS ITALY S P A (IT) | 2015-02-25 | — | — | EP | claimed |
| US-20110028726-A1 | METHOD FOR PREPARING ARGATROBAN MONOHYDRATE AND A PROCESS FOR ITS SYNTHESIS | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2011-02-03 | — | — | US | claimed |
| CN-101914133-A | Directional synthesis method for 21(S) argatroban | TIANJIN WEIJIE TECHNOLOGY CO LTD | 2010-12-15 | — | — | CN | claimed |
| CN-101914132-A | Crystal structure of 21(S) argatroban | TIANJIN WEIJIE TECHNOLOGY CO LTD | 2010-12-15 | — | — | CN | claimed |
| CN-100586946-C | Argatroban separation method | TIANJIN WEIJIE TECHNOLOGY CO LTD | 2010-02-03 | — | — | CN | claimed |
| WO-2009124906-A2 | METHOD FOR PREPARING ARGATROBAN MONOHYDRATE | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2009-10-15 | — | — | WO | claimed |
| CN-100467022-C | Application of 21(S) argatroban | TIANJIN WEIJIE TECHNOLOGY CO L (CN) | 2009-03-11 | — | — | CN | claimed |
| CN-100427480-C | Process for preparing argatroban hydrate | TIANJIN WEIJIE TECHNOLOGY CO L (CN) | 2008-10-22 | — | — | CN | claimed |
| CN-101235031-A | Directional synthesis and crystal structure of 21 argatroban and preparation of monohydrate | TIANJIN WEIJIE TECHNOLOGY CO L (CN) | 2008-08-06 | — | — | CN | claimed |
| CN-101032485-A | Application of 21(S) argatroban | TIANJIN WEIJIE TECHNOLOGY CO L (CN) | 2007-09-12 | — | — | CN | claimed |
| CN-1951937-A | Process for preparing argatroban hydrate | TIANJIN WEIJIE TECHNOLOGY CO L (CN) | 2007-04-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028726-A1 | METHOD FOR PREPARING ARGATROBAN MONOHYDRATE AND A PROCESS FOR ITS SYNTHESIS | ASS1, PRMT7, PRMT3 | F2 293/4885PRSS1 1872/4885F10 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.